Following a strategic acquisition, Swixx BioPharma expects a turnover exceeding one billion

Swixx BioPharma was created to replace biopharma, OTC and medical device multinationals’ subsidiaries in those countries, or therapeutic areas, that its partners choose not to enter, or to exit. The company based in den canton of Zug expands into Latin America with the signature of an agreement to acquire 100% of the equity of Pharma Consulting Group S.A. the holding company of Laboratorios Biopas SA.

With operational headquarters in Bogota, Colombia, Biopas is one of Latin America’s leading independent marketing and distribution companies for international biopharmaceutical firms. Biopas has a presence in 20 countries, including Latam’s “Top 5“ markets of Argentina, Brazil, Chile, Colombia & Mexico. With the addition of $220 million in sales, over 300 employees and therapeutic coverage in Neurology, Oncology, Immunology, Gastroenterology, Rare Diseases and Specialty, acquisition extends & transforms Swixx BioPharma’s footprint. Closing of the transaction is expected after relevant regulatory approvals, anticipated in June-July 2024.

This acquisition follows on the entry of Swixx BioPharma into the Middle East region in September 2023 and marks another important step towards fulfilling Swixx’s mission to become the preferred partner for biopharma companies seeking indirect routes to launch their medicines.  Through Biopas’ comprehensive Latam continental coverage, Swixx will now be able to provide a compelling offering covering Central and Eastern Europe, CIS/Eurasia, MENA and now Latin America.  

Swixx BioPharma has over 1,300 employees and sales likely to exceed a billion Euros in 2024.  The company is one of the fastest-growing, largest, independent, intercontinental commercial platforms for the biopharmaceutical industry.

(Press release / SK)